Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?

Ann Transl Med. 2019 Jul;7(Suppl 3):S140. doi: 10.21037/atm.2019.06.35.
No abstract available

Publication types

  • Editorial
  • Comment